AU2002365136A1 - Compositions and methods for controlled release - Google Patents

Compositions and methods for controlled release

Info

Publication number
AU2002365136A1
AU2002365136A1 AU2002365136A AU2002365136A AU2002365136A1 AU 2002365136 A1 AU2002365136 A1 AU 2002365136A1 AU 2002365136 A AU2002365136 A AU 2002365136A AU 2002365136 A AU2002365136 A AU 2002365136A AU 2002365136 A1 AU2002365136 A1 AU 2002365136A1
Authority
AU
Australia
Prior art keywords
compositions
methods
controlled release
release
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002365136A
Other languages
English (en)
Other versions
AU2002365136A8 (en
Inventor
Michael D. Dake
Jacob M. Waugh
Arthur H. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revance Therapeuticals Inc
Original Assignee
Essentia Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essentia Biosystems Inc filed Critical Essentia Biosystems Inc
Publication of AU2002365136A8 publication Critical patent/AU2002365136A8/xx
Publication of AU2002365136A1 publication Critical patent/AU2002365136A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
AU2002365136A 2001-10-18 2002-10-17 Compositions and methods for controlled release Abandoned AU2002365136A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33634401P 2001-10-18 2001-10-18
US60/336,344 2001-10-18
PCT/US2002/033558 WO2003060142A2 (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release

Publications (2)

Publication Number Publication Date
AU2002365136A8 AU2002365136A8 (en) 2003-07-30
AU2002365136A1 true AU2002365136A1 (en) 2003-07-30

Family

ID=23315656

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002365136A Abandoned AU2002365136A1 (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release

Country Status (5)

Country Link
EP (1) EP1446008A4 (ja)
JP (1) JP2005523890A (ja)
AU (1) AU2002365136A1 (ja)
CA (1) CA2464131A1 (ja)
WO (1) WO2003060142A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145813A1 (en) 2008-03-04 2009-12-03 Qd Vision, Inc. Particles including nanoparticles, uses thereof, and methods
KR101865888B1 (ko) 2009-09-09 2018-06-08 삼성전자주식회사 나노입자들을 포함하는 입자, 그의 용도, 및 방법
WO2011031876A1 (en) 2009-09-09 2011-03-17 Qd Vision, Inc. Formulations including nanoparticles
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
JP2016183434A (ja) * 2015-03-26 2016-10-20 国立大学法人京都大学 表面修飾基材

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985554A (en) * 1994-11-02 1999-11-16 Takeda Chemical Industries, Ltd. Method of probing the function of proteins or peptides encoded by partially sequenced cDNAs by inhibiting protein synthesis with antisense oligonucleotides
GB2341390B (en) * 1997-05-21 2000-11-08 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
AU3363399A (en) * 1998-03-27 1999-10-18 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)
US6333194B1 (en) * 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6232068B1 (en) * 1999-01-22 2001-05-15 Rosetta Inpharmatics, Inc. Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies
WO2001024775A1 (en) * 1999-10-01 2001-04-12 Essentia Biosystems, Inc. Gel-forming compositions
IN2014DN10834A (ja) * 2001-09-17 2015-09-04 Psivida Inc
US20030134811A1 (en) * 2001-10-09 2003-07-17 John Jackson Methods and compositions comprising hydroxyapatite useful for the administration of therapeutic agents

Also Published As

Publication number Publication date
WO2003060142A2 (en) 2003-07-24
EP1446008A2 (en) 2004-08-18
AU2002365136A8 (en) 2003-07-30
CA2464131A1 (en) 2003-07-24
EP1446008A4 (en) 2006-08-16
WO2003060142A9 (en) 2003-08-21
JP2005523890A (ja) 2005-08-11
WO2003060142A3 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
AU2002300377A1 (en) Compositions for controlled release
AU2002357119A1 (en) Mitocidal compositions and methods
GB0218157D0 (en) Compositions for controlled release
AU2002229140A1 (en) Controlled release pharmaceutical composition
AU2002361623A1 (en) Methods and compositions for chromatography
AU2001293189A1 (en) Compositions and methods for regulating apoptosis
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2002241114A1 (en) Composition
AU2002357748A1 (en) Osteopontin-related compositions and methods
AU2002351388A1 (en) Methods and compositions for controlled release of drugs
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
AU2002359694A1 (en) Compounds and methods
AU2002345878A1 (en) Ilt3 and ilt4-related compositions and methods
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2002365136A1 (en) Compositions and methods for controlled release
AU2003212866A1 (en) Controlled release compositions and methods for using same
AU2002245510A1 (en) Method and composition for embalming
AU2001283226A1 (en) Methods and compositions for inhibiting rad51
AU2003275240A1 (en) Methods and compositions for soluble cpg15
AU2002359869A1 (en) Pak5-related compositions and methods
AU2002246221A1 (en) Method and composition
AU2002307070A1 (en) Method and composition for controlled release acarbose formulations
AUPQ994800A0 (en) Compositions and methods for immunotherapy
AUPQ821300A0 (en) Compositions and methods for immunotherapy
AU2002338412A1 (en) Controlled release particles

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase